Werewolf Therapeutics, Inc.
HOWLHealthcare|Biotechnology|US
$1.01
-0.01 (-0.98%)
DCF Value
$1.02
Tangible Book / Share
$0.34
Cash / Share
$0.45
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06939283 A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | P1P2 | Completed | 24 | Open-label | WTX-330 |
| NCT05678998 WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | P1 | Completed | 25 | Open-label | WTX-330 |
| NCT05479812 Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Metastatic Solid Tumor, Advanced Solid Tumor | P1 | Completed | 156 | Open-label | WTX-124, pembrolizumab |